Up-regulation of serotonin receptor 2B mRNA and protein in the peri-infarcted area of aged rats and stroke patients

Oncotarget

Volumn 7, Issue 14, 2016, Pages 17415-17430

  Buga, Ana Maria ^a,b   Ciobanu, Ovidiu ^b,f   Badescu, George Mihai ^b   Bogdan, Catalin ^b   Weston, Ria ^c   Slevin, Mark ^c   Di Napoli, Mario ^d,e   Popa Wagner, Aurel ^a  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^b UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

^c MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

^d SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

^e Neurological Section   (Italy)

^f VIVANTES HOSPITAL   (Germany)

Author keywords

Aging; Gerotarget; Neurogenesis; Post stroke depression; Serotonin receptor type B; Stroke

Indexed keywords

FLUOXETINE; HTR2B PROTEIN; SEROTONIN 2 RECEPTOR; SEROTONIN RECEPTOR 2A; SEROTONIN RECEPTOR 2B; UNCLASSIFIED DRUG; MESSENGER RNA; SEROTONIN 2B RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGE; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN INFARCTION; BRAIN SIZE; CELL ACTIVATION; CEREBROVASCULAR ACCIDENT; DEPRESSION; DISEASE COURSE; FEMALE; FORCED SWIM TEST; HISTOLOGY; HUMAN; MALE; MICROGLIA; MIDDLE AGED; NERVE CELL; NERVE CELL DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SUBVENTRICULAR ZONE; SURVIVAL TIME; UPREGULATION; VERY ELDERLY; ANIMAL; BIOSYNTHESIS; BRAIN; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; PSYCHOLOGY; RANDOMIZATION; SPRAGUE DAWLEY RAT;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANIMALS; BRAIN; DEPRESSION; DISEASE MODELS, ANIMAL; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; NEUROGENESIS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2B; RNA, MESSENGER; SEROTONIN UPTAKE INHIBITORS; STROKE; UP-REGULATION;

EID: 84975481412     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8277     Document Type: Article

References (73)

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM et al. Heart disease and stroke statistics-2015 update: a report from the AmericanHeart Association. Circulation. 2015;131:e29-e322.
2. Ay H, Koroshetz WJ, Vangel M, Benner T, Melinosky C, Zhu M, Menezes N, Lopez CJ, and Sorensen AG. Conversion of ischemic brain tissue into infarction increases with age. Stroke. 2005; 36:2632-2636.
3. Bergerat A, Decano J, Wu CJ, Choi H, Nesvizhskii AI, Moran AM, Ruiz-Opazo N, Steffen M, and Herrera VL. Prestroke proteomic changes in cerebral microvessels in stroke-prone, transgenic [hCETP]-Hyperlipidemic, Dahl salt-sensitive hypertensive rats. Mol Med. 2001; 17:588-598.
4. Gokcay F, Arsava EM, Baykaner T, Vangel M, Garg P, Wu O, Singhal AB, Furie KL, Sorensen AG, and Ay H. Age dependent susceptibility to infarct growth in women. Stroke. 2011; 42:947-951.
5. Popa-Wagner A, Carmichael ST, Kokaia Z, Kessler C, and Walker LC. The response of the aged brain to stroke: too much, too soon? Curr Neurovasc Res. 2007; 4:216-227.
6. Loubinoux I, Kronenberg G, Endres M, Schumann-Bard P, Freret T, and Filipkowski RK. Post-stroke depression: mechanisms, translation and therapy. J Cell Mol Med. 2012; 16:1961-1969.
7. Pompili M, Venturini P, Lamis DA, Giordano G, Serafini G, Belvederi Murri M, Amore M, Girardi P. Suicide in stroke survivors: epidemiology and prevention. Drugs Aging. 2015; 32:21-29.
8. Duman RS, and Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci. 2012; 35:47-56.
9. Knol MJ, Twisk JW, Beekman AT, Heine RJ, Snoek FJ, and Pouwer F. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia. 2006; 49:837-845.
10. Soriano-Tárraga C, Jiménez-Conde J, Giralt-Steinhauer E, Mola-Caminal M, Vivanco-Hidalgo RM, Ois A, Rodríguez-Campello A, Cuadrado-Godia E, Sayols-Baixeras S, Elosua R, Roquer J. Epigenome-wide association study identifies TXNIP gene associated with type 2 diabetes mellitus and sustained hyperglycemia. Hum Mol Genet. 2016; 25:609-619.
11. Slevin M, Matou S, Zeinolabediny Y, Corpas R, Weston R, Liu D, Boras E, Di Napoli M, Petcu E, Sarroca S, Popa-Wagner A, Love S, Font MA, Potempa LA, Al-Baradie R, Sanfeliu C, Revilla S, Badimon L, Krupinski J. Monomeric C-reactive protein-a key molecule driving development of Alzheimer'sdisease associated with brain ischaemia? Sci Rep. 2015; 5:13281. doi: 10.1038/srep13281.
12. Garriga M, Milà M, Mir M, Al-Baradie R, Huertas S, Castejon C, Casas L, Badenes D, Giménez N, Font MA, Gonzalez JM, Ysamat M, Aguilar M et al. (123)I-FPCIT SPECT imaging in early diagnosis of dementia in patients with and without a vascular component. Front Syst Neurosci. 2015; 9:99. doi: 10.3389/fnsys.2015.00099.
13. Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM, Krishnan KR, Nemeroff CB, Bremner JD, Carney RM, Coyne JC, Delong MR, Frasure-Smith N, Glassman AH, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry. 2005; 58:175-189.
14. Gildengers AG, Whyte EM, Drayer RA, Soreca I, Fagiolini A, Kilbourne AM, Houck PR, Reynolds CF 3rd, Frank E, Kupfer DJ, and Mulsant BH. Medical burden in latelife bipolar and major depressive disorders. Am J Geriatr Psychiatry. 2008; 16:194-200.
15. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, and Walters EE. Lifetime prevalence and age-ofonset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62:593-602.
16. Krishnan V, and Nestler EJ. The molecular neurobiology of depression. Nature. 2008; 455:894-902.
17. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, and Fava M. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006; 163:28-40.
18. Corominas R, Sobrido MJ, Ribasés M, Cuenca-León E, Blanco-Arias P, Narberhaus B, Roig M, Leira R, López-González J, Macaya A, and Cormand B. Association study of the serotoninergic system in migraine in the Spanish population. Am J Med Genet B Neuropsychiatr Genet. 2010; 153B:177-184.
19. Leysen JE. 5-HT2 receptors. Curr Drug Targets CNS Neurol Disord. 2004; 3:11-26.
20. Clemett DA, Punhani T, Duxon MS, Blackburn TP, and Fone KC. Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS. Neuropharmacology 2000; 39:123-132.
21. Duxon MS, Flanigan TP, Reavley AC, Baxter GS, Blackburn TP, and Fone KC. Evidence for expression of the 5-hydroxytryptamine-2B receptor protein in the rat central nervous system. Neuroscience. 1997; 76:323-329.
22. Badan I, Buchhold B, Hamm A, Gratz M, Walker LC, Platt D, Kessler C, and Popa-Wagner A. Accelerated glial reactivity to stroke in aged rats correlates with reduced functional recovery. J Cereb Blood Flow Metab. 2003; 23:845-854.
23. Schmidt H, Zeginigg M, Wiltgen M, Freudenberger P, Petrovic K, Cavalieri M, Gider P, Enzinger C, Fornage M, Debette S, Rotter JI, Ikram MA, Launer LJ, and Schmidt R. CHARGE consortium Neurology working group. Genetic variants of the NOTCH3 gene in the elderly and magnetic resonance imaging correlates of age-related cerebral small vessel disease. Brain. 2011; 134:3384-3397.
24. Buga AM, Sascau M, Pisoschi C, Herndon JG, Kessler C, and Popa-Wagner A. The genomic response of the ipsilateral and contralateral cortex to stroke in aged rats. J Cell Mol Med. 2008; 12: 2731-2753.
25. Buga AM, Scholz CJ, Kumar S, Herndon JG, Alexandru D, Cojocaru GR, Dandekar T, and Popa-Wagner A. Identification of new therapeutic targets by genome-wide analysis of gene expression in the ipsilateral cortex of aged rats after stroke. PLoS ONE. 2012; 7: e50985. doi:10.1371/journal.pone.0050985.
26. Buchhold B, Mogoanta L, Suofu Y, Hamm A, Walker L, Kessler C, and Popa-Wagner A. Environmental enrichment improves functional and neuropathological indices following stroke in young and aged rats. Restorative Neurol Neurosci. 2007; 25:1-18.
27. Popa-Wagner A, Stocker K, Balseanu A, Rogalewski A, Diederich K, Minnerup J, Margaritescu C, and Schäbitz WR. Effects of granulocyte-colony stimulating factor after stroke in aged rats. Stroke. 2010; 41:1027-1031.
28. Rehncrona S, Rosén I, and Siesjö BK. Brain lactic acidosis and ischemic cell damage: 1. Biochemistry and neurophysiology. J Cereb Blood Flow Metab. 1981; 1:297-311.
29. Cryan JF, Page ME, and Lucki I. Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine in a modified forced swim test. Eur J Pharmacol. 2002; 436:197-205.
30. Strekalova T, Spanagel R, Bartsch D, Henn FA, and Gass P. Stress-induced anhedonia in mice is associated with deficits in forced swimming and exploration. Neuropsychopharmacology. 2004; 29:2007-2017.
31. Popa-Wagner A, Badan I, Walker L, Groppa S, Patrana N, and Kessler C. Accelerated infarct development, cytogenesis and apoptosis following transient cerebral ischemia in aged rats. Acta Neuropathol. 2007; 113:277-293.
32. Popa-Wagner A, Schroder E, Walker LC, and Kessler C. beta-Amyloid precursor protein and ss-amyloid peptide immunoreactivityin the rat brain after middle cerebral arteryocclusion: effect of age. Stroke. 1998; 29:2196-2202.
33. Perez-Caballero L, Torres-Sanchez S, Bravo L, Mico JA, and Berrocoso E. Fluoxetine: a case history of its discovery and preclinical development. Expert Opin Drug Discov. 2014; 9:567-578.
34. David DJ, Samuels BA, Rainer Q, Wang JW, Marsteller D, Mendez I, Drew M, Craig DA, Guiard BP, Guilloux JP, Artymyshyn RP, Gardier AM, Gerald C, et al. Neurogenesis-dependent and-independent effects of fluoxetine in an animal model of anxiety/depression. Neuron. 2009; 62:479-493.
35. Joseph C, Buga AM, Vintilescu R, Balseanu AT, Moldovan M, Junker H, Walker L, Lotze M, and Popa-Wagner A. Prolonged gaseous hypothermia prevents the upregulation of phagocytosis-specific protein Annexin 1 and causes low amplitude EEG activity in the aged rat brain after cerebral ischemia. J Cereb Blood Flow Metab. 2012; 32:1632-1642.
36. Hawthorne AL, Wylie CJ, Landmesser LT, Deneris ES, and Silver J. Serotonergic neurons migrate radially through the neuroepithelium by dynamin-mediated somal translocation. J Neurosci. 2010;30:420-430.
37. Rodríguez JJ, Noristani HN, Verkhratsky A. The serotonergic system in ageing and Alzheimer's disease. Prog Neurobiol. 2012; 99:15-41
38. Hattori S, Hashimoto R, Miyakawa T, Yamanaka H, Maeno H, Wada K, and Kunugi H. Enriched environments influence depression-related behavior in adult mice and the survival of newborn cells in their hippocampi. Behav Brain Res. 2007; 180:69-76.
39. Jha S, Dong B, and Sakata K. Enriched environment treatment reverses depression-like behavior and restores reduced hippocampal neurogenesis and protein levels of brain-derived neurotrophic factor in mice lacking its expression through promoter IV. Transl Psychiatry. 2011; 1: e40. doi: 10.1038/tp.2011.33.
40. Niebert M, Vogelgesang S, Koch UR, Bischoff AM, Kron M, Bock N, and Manzke T. Expression and function of serotonin 2A and 2B receptors in the mammalian respiratory network.PLoS One. 2011; 6:e21395. doi: 10.1371/journal. pone.0021395.
41. Peng L, Gu L, Li B, and Hertz L. Fluoxetine and all other SSRIs are 5-HT2B Agonists-Importance for their Therapeutic Effects. Curr Neuropharmacol. 2014; 12:365-339.
42. Quaranta D, Marra C, and Gainotti G. Post-stroke depression: Main phenomenological clusters and their relationships with clinical measures. Behav Neurol. 2012; 25:303-310.
43. Zopf DA, das Neves LA, Nikula KJ, Huang J, Senese PB, and Gralinski MR. C-122, a novel antagonist of serotonin receptor 5-HT2B, prevents monocrotaline-induced pulmonary arterial hypertension in rats. Eur J Pharmacol. 2011; 670:195-203.
44. McCreary AC, and Cunningham KA. Effects of the 5-HT2C/2B antagonist SB 206553 on hyperactivity induced by cocaine. Neuropsychopharmacology. 1999; 20:556-564.
45. Kennett GA. 5-HT drugs and eating disorders. IDrugs. 1998; 1:456-470.
46. Launay JM, Schneider B, Loric S, Da Prada M, and Kellermann O. Serotonin transport and serotonin transporter-mediated antidepressant recognition are controlled by 5-HT2B receptor signaling in serotonergic neuronal cells. FASEB J. 2006; 20:1843-1854.
47. Doly S, Valjent E, Setola V, Callebert J, Hervé D, Launay JM, and Maroteaux L. Serotonin 5-HT2B receptors are required for 3, 4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro. J Neurosci. 2008; 28:2933-2940.
48. van Dalen JW, Moll van Charante EP, Nederkoorn PJ, van Gool WA, Richard E. Poststroke apathy. Stroke. 2013; 44:851-860.
49. Robert P, Onyike CU, Leentjens AF, Dujardin K, Aalten P, Starkstein S, Verhey FR, Yessavage J, Clement JP, Drapier D, Bayle F, Benoit M, Boyer P et al. Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders. Eur Psychiatry. 2009; 24:98-104
50. Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991; 3:243-254
51. Starkstein SE, Fedoroff JP, Price TR, Leiguarda R, and Robinson RG. Apathy following cerebrovascular lesions. Stroke. 1993; 24:1625-1630
52. Hama S, Yamashita H, Shigenobu M, Watanabe A, Hiramoto K, and Kurisu K. Depression or apathy and functional recovery after stroke. Int J Geriatr Psychiatry. 2007; 22:1046-1051.
53. Okada K, Kobayashi S, Yamagata S, Takahashi K, and Yamaguchi S. Poststroke apathy and regional cerebral blood flow. Stroke. 1997; 28:2437-2441.
54. Andersson S, Krogstad JM, and Finset A. Apathy and depressed mood in acquired brain damage: relationship to lesion localization and psychophysiological reactivity. Psychol Med. 1999; 29:447-456.
55. Murray KC, Stephens MJ, Ballou EW, Heckman CJ, and Bennett DJ. Motoneuron excitability and muscle spasms are regulated by 5-HT2B and 5-HT2C receptor activity. J Neurophysiol. 2011; 105:731-748.
56. Brodaty H, Sachdev PS, Withall A, Altendorf A, Valenzuela MJ, and Lorentz L. Frequency and clinical, neuropsychological and neuroimaging correlates of apathy following stroke-the Sydney Stroke Study. Psychol Med. 2005; 35:1707-1716.
57. Lampe IK, Kahn RS, and Heeren TJ. Apathy, anhedonia, and psychomotor retardation in elderly psychiatric patients and healthy elderly individuals. J Geriatr Psychiatry Neurol. 2001; 14:11-16.
58. Krishnan KR, and McDonald WM. Arteriosclerotic depression. Med Hypotheses. 1995; 44:111-115.
59. Samuels BA, Anacker C, Hu A, Levinstein MR, Pickenhagen A, Tsetsenis T, Madroñal N, Donaldson ZR, Drew LJ, Dranovsky A, Gross CT, Tanaka KF, Hen R. 5-HT1A receptors on mature dentate gyrus granule cells are critical for the antidepressant response. Nat Neurosci. 2015; 18:1606-16. doi: 10.1038/nn.4116.
60. Liu D, Wang Z, Liu S, Wang F, Zhao S, Hao A. Anti-inflammatory effects of fluoxetine in lipopolysaccharide(LPS)-stimulated microglial cells. Neuropharmacology. 2011; 61:592-599.
61. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000; 20:9104-9110.
62. Sun X, Zhou Z, Liu T, Zhao M, Zhao S, Xiao T, Jolkkonen J, and Zhao C. Fluoxetine Enhances Neurogenesis in Aged Rats with Cortical Infarcts, but this is not Reflected in a Behavioral Recovery. J Mol Neurosci. 2016; 58:233-42. doi: 10.1007/s12031-015-0662-y.
63. van Praag H, Schinder AF, Christie BR, Toni N, Palmer TD, Gage FH. Functional neurogenesis in the adult hippocampus. Nature. 2002; 415:1030-1034.
64. Hermann DM, and Chopp M. Promoting brain remodelling and plasticity for stroke recovery: therapeutic promise and potential pitfalls of clinical translation. Lancet Neurol. 2012; 11:369-380.
65. Jinno S. Decline in adult neurogenesis during aging follows a topographic pattern in the mouse hippocampus. J Comp Neurol. 2011; 519:451-466.
66. Enwere E, Shingo T, Gregg C, Fujikawa H, Ohta S, and Weiss S. Aging results in reduced epidermal growth factor receptor signaling, diminished olfactory neurogenesis, and deficits in fine olfactory discrimination. J Neurosci. 2004; 24:8354-8365.
67. Dentel C, Palamiuc L, Henriques A, Lannes B, Spreux-Varoquaux O, Gutknecht L, René F, Echaniz-Laguna A, Gonzalez de Aguilar JL, Lesch KP, Meininger V, Loeffler JP, Dupuis L. Degeneration of serotonergic neurons in amyotrophic lateral sclerosis: a link to spasticity. Brain. 2013; 136:483-493.
68. Moraga A, Pradillo JM, García-Culebras A, Palma-Tortosa S, Ballesteros I, Hernández-Jiménez M, Moro MA, Lizasoain I. Aging increases microglial proliferation, delays cell migration, and decreases cortical neurogenesis after focal cerebral ischemia. J Neuroinflammation. 2015; 12:87. doi: 10.1186/s12974-015-0314-8.
69. Couillard-Despres S, Wuertinger C, Kandasamy M, Caioni M, Stadler K, Aigner R, Bogdahn U, Aigner L. Ageing abolishes the effects of fluoxetine on neurogenesis. Mol Psychiatry. 2009; 14:856-864.
70. Li WL, Cai HH, Wang B, Chen L, Zhou QG, Luo CX, Liu N, Ding XS, Zhu DY. Chronic fluoxetine treatment improves ischemia-induced spatial cognitive deficits through increasing hippocampal neurogenesis after stroke. J Neurosci Res. 2009; 87:112-122.
71. Darsalia V, Heldmann U, Lindvall O, Kokaia Z. Strokeinduced neurogenesis in aged brain. Stroke. 2005; 36:1790-1795.
72. Lindvall O, Kokaia Z. Neurogenesis following Stroke Affecting the Adult Brain. Cold Spring Harb Perspect Biol. 2015; 7. pii: a019034. doi:10.1101/cshperspect.a019034.
73. Arreola R, Becerril-Villanueva E, Cruz-Fuentes C, Velasco-Velázquez MA, Garcés-Alvarez ME, Hurtado-Alvarado G, Quintero-Fabian S, PavónL. Immunomodulatory effects mediated by serotonin. J Immunol Res. 2015;2015:354957. doi: 10.1155/2015/354957.